Literature DB >> 29438362

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Edward J Saunders, Tokhir Dadaev, Daniel A Leongamornlert, Ali Amin Al Olama, Sara Benlloch, Graham G Giles, Fredrik Wiklund, Henrik Grönberg, Christopher A Haiman, Johanna Schleutker, Børge G Nordestgaard, Ruth C Travis, David Neal, Nora Pasayan, Kay-Tee Khaw, Janet L Stanford, William J Blot, Stephen N Thibodeau, Christiane Maier, Adam S Kibel, Cezary Cybulski, Lisa Cannon-Albright, Hermann Brenner, Jong Y Park, Radka Kaneva, Jyotsna Batra, Manuel R Teixeira, Hardev Pandha, Koveela Govindasami, Ken Muir, Douglas F Easton, Rosalind A Eeles, Zsofia Kote-Jarai.   

Abstract

This corrects the article DOI: 10.1038/bjc.2016.50.

Entities:  

Year:  2018        PMID: 29438362      PMCID: PMC5877430          DOI: 10.1038/bjc.2017.468

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


Correction to: British Journal of Cancer (2016) 114, 945–952; doi:10.1038/bjc.2016.50; published online 10 March 2016 Following the publication of this manuscript, it was recognised that some of the names included in the list of The UK Genetic Prostate Cancer Study Collaborators had not been presented in full. Full names have now been provided for the majority of these collaborators and their names appear correctly below: Mohammed L Al-Sudani, Dr Mark Beresford, Barnaby G Chappell, Marcus J Drake, Dr Baba M Ghana, Donald Macdonald, Shoukat H Memon, Moiketse Mokete, Jan D Nawrocki, Dr Graham Read, Edward W J Rowe, Dr Richard E Shaffer, Dr Lucy Side, Vaikantum Srinivasan.
  2 in total

1.  Group testing in mediation analysis.

Authors:  Andriy Derkach; Steven C Moore; Simina M Boca; Joshua N Sampson
Journal:  Stat Med       Date:  2020-05-04       Impact factor: 2.497

2.  Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.

Authors:  Xiaonan Zheng; Hang Xu; Xianyanling Yi; Tianyi Zhang; Qiang Wei; Hong Li; Jianzhong Ai
Journal:  Mol Cancer       Date:  2021-12-06       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.